Showing 6721-6730 of 8079 results for "".
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into
- Dupixent Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe ADhttps://practicaldermatology.com/news/dupixent-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-ad/2460619/The European Commission (EC) has given its nod to Dupixent (dupilumab) for children 6 to 11 with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients. "As the parent
- Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institutionhttps://practicaldermatology.com/news/crown-aesthetics-scores-class-iia-ce-certification-for-skinpen-precision/2460614/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and Morehttps://practicaldermatology.com/news/eadv-congress-update-insights-on-psoriasis-ad-uv-protection-covid-19-and-more/2460588/From updates on investigational treatments for dermatologic diseases to emerging healthcare trends, data from the 29th EADV Congress, EADV Virtual suggest new directions in patient care. Psoriasis: Results from the phas